Back

Predictors of implantable cardio-defibrillator activation in patients with hypertrophic cardiomyopathy at primary prevention of sudden cardiac death

11 May 2024 (11:40 - 13:00)
Organised by: Logo
Congress Presentation Part of: ePosters in arrhythmias and device therapy 2 Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Miguel Marques Antunes

Centro Hospitalar Universitario de Lisboa Central, E.P.E., Lisboa (Portugal)

5 More presentations in this session

Presentation thumbnail
Gender difference in life threatening arrhythmias in patients with non-ischaemic cardiomyopathy
Doctor I. Chung (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Gender difference in clinical outcomes in patients with hypertrophic cardiomyopathy
Doctor I. Chung (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Unraveling the story of hundreds of syncopes and pre-syncopes
Doctor M. Castro (Guimaraes, PT)
Abstract Slides Video
Presentation thumbnail
Ajmaline testing in Brugada Syndrome: a comparative analysis of diagnostic protocols and clinical outcomes across two hospital centers
Doctor C. Oliveira (Porto, PT)
Abstract Slides Video
Presentation thumbnail
The risk of life-threatening forecast scale
Assistant Professor N. Kulaiets (Ivano-Frankivsk, UA)
Abstract Slides

Access the full session

Session thumbnail
ePosters in arrhythmias and device therapy 2

The Event

Event poster

Heart Failure 2024

11 May 2024 11:40 CET
You may be interested in
thumbnail
Congress Presentation
Predictors of recurrent ventricular arrhythmias and the impact of genetic testing in a hypertrophic cardiomyopathy patient cohort at long term follow up
thumbnail
Congress Presentation
Sudden cardiac death HCM risk scores in apical hypertrophic cardiomyopathy: an unmet need in clinical practice
thumbnail
Congress Presentation
Long-term follow-up in patients with hypertrophic cardiomyopathy after defibrillator implantation: analysis of appropriate and inappropriate therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources